4-[3-(4-chloro-2,3-dihydro-1H-benzimidazol-2-yl)-2H-indazol-5-yl]isoquinoline

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 4-[3-(4-chloro-2,3-dihydro-1H-benzimidazol-2-yl)-2H-indazol-5-yl]isoquinoline
• 化学式: C₂₃H₁₆ClN₅
• 分子量: 397.9
• InChiKey: UNIFRVNLSHYTMJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  29
• 可旋转键数：
  2
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  65.6
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• [EN] 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF<br/>[FR] INHIBITEURS DE 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE DE LA VOIE DE SIGNALISATION PAR WNT ET LEURS UTILISATIONS THÉRAPEUTIQUES
  申请人：SAMUMED LLC

  公开号：WO2014110086A2

  公开（公告）日：2014-07-17

  Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.